We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
+9.27%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$423M
AUM Growth
+$4.74M
(+1.1%)
Cap. Flow
-$21.3M
Cap. Flow
% of AUM
-5.03%
Top 10 Holdings %
Top 10 Hldgs %
48.91%
Holding
89
New
6
Increased
19
Reduced
26
Closed
5
Top Buys
| 1 |
Lexeo Therapeutics
LXEO
|
+$2.99M |
| 2 |
IDEAYA Biosciences
IDYA
|
+$1.87M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$1.69M |
| 4 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$1.2M |
| 5 |
Allogene Therapeutics
ALLO
|
+$1.19M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$7.9M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$4.27M |
| 3 |
Viking Therapeutics
VKTX
|
+$3.73M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$2.69M |
| 5 |
TSVT
2seventy bio
TSVT
|
+$1.9M |
Sector Composition
| 1 | Healthcare | 86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $39.7M | 9.37% |
401,505
-43,500
| -10% | -$4.27M |
|
2
Stereotaxis
STXS
$160M
| $27.9M | 6.59% |
13,680,554
| – | – |
|
3
Revolution Medicines
RVMD
$39.3B
| $23.5M | 5.55% |
517,994
+6,100
| +1% | +$266K |
|
4
Cytokinetics
CYTK
$11.2B
| $21M | 4.97% |
398,100
| – | – |
|
|
MRUS
5
DELISTED
Merus
MRUS
| $20.6M | 4.87% |
412,573
+3,128
| +0.8% | +$163K |
|
6
AtriCure
ATRC
$1.75B
| $18M | 4.25% |
641,673
+2,500
| +0.4% | +$61.6K |
|
|
7
IDEAYA Biosciences
IDYA
$3.55B
| $14.9M | 3.53% |
471,410
+49,197
| +12% | +$1.87M |
|
8
iShares Biotechnology ETF
IBB
$9.23B
| $14.9M | 3.53% |
102,500
| – | – |
|
9
Ascendis Pharma A/S
ASND
$17.5B
| $13.4M | 3.16% |
89,572
+8,600
| +11% | +$1.16M |
|
10
Axogen
AXGN
$2.05B
| $13.1M | 3.1% |
935,894
| – | – |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $11.3M | 2.66% |
121,763
+17,000
| +16% | +$1.69M |
|
12
Xenon Pharmaceuticals
XENE
$6.55B
| $10.8M | 2.55% |
273,739
| – | – |
|
|
DAWN
13
DELISTED
Day One Biopharmaceuticals
DAWN
| $10.5M | 2.47% |
750,363
+83,900
| +13% | +$1.2M |
|
|
14
Syndax Pharmaceuticals
SNDX
$2.08B
| $10.1M | 2.4% |
526,702
-130,372
| -20% | -$2.69M |
|
15
Biohaven
BHVN
$2.25B
| $9.35M | 2.21% |
187,130
-31,600
| -14% | -$1.23M |
|
16
Tandem Diabetes Care
TNDM
$1.06B
| $8.66M | 2.05% |
204,208
| – | – |
|
|
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
| $8.38M | 1.98% |
723,678
-83,295
| -10% | -$1.05M |
|
18
Neurocrine Biosciences
NBIX
$17.2B
| $8.02M | 1.89% |
69,615
-2,000
| -3% | -$274K |
|
19
Kura Oncology
KURA
$1B
| $7.98M | 1.89% |
408,368
-15,132
| -4% | -$307K |
|
|
20
Viking Therapeutics
VKTX
$4.44B
| $7.95M | 1.88% |
125,616
-63,501
| -34% | -$3.73M |
|
21
Edgewise Therapeutics
EWTX
$4.36B
| $6.08M | 1.44% |
227,906
-62,291
| -21% | -$1.24M |
|
22
UroGen Pharma
URGN
$1.95B
| $5.83M | 1.38% |
458,915
-10,085
| -2% | -$150K |
|
23
BioCryst Pharmaceuticals
BCRX
$2.41B
| $5.07M | 1.2% |
667,000
-37,500
| -5% | -$285K |
|
24
DexCom
DXCM
$28.4B
| $4.39M | 1.04% |
65,552
| – | – |
|
25
Keros Therapeutics
KROS
$213M
| $4.28M | 1.01% |
73,754
+6,000
| +9% | +$296K |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML